Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Christophe Douat
|
| gptkbp:collaboratesWith |
gptkb:Teva_Pharmaceuticals
gptkb:Serum_Institute_of_India |
| gptkbp:country |
gptkb:France
|
| gptkbp:developedBy |
mdc-CWM
mdc-IRM mdc-TJK |
| gptkbp:focusesOn |
long-acting injectable drugs
|
| gptkbp:foundedIn |
2002
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:Montpellier,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
MedinCell
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Euronext_Paris
|
| gptkbp:notableProduct |
Uzedy
|
| gptkbp:numberOfEmployees |
~140
|
| gptkbp:platform |
BEPO
|
| gptkbp:specializesIn |
sustained-release drug delivery
|
| gptkbp:stockExchange |
gptkb:Euronext_Paris
|
| gptkbp:stockSymbol |
MEDCL
|
| gptkbp:Uzedy |
treatment for schizophrenia
|
| gptkbp:website |
https://www.medincell.com/
|
| gptkbp:bfsParent |
gptkb:Nanomi_B.V.
|
| gptkbp:bfsLayer |
8
|